Patients treated with a combination of insulin + OADs have benefited from the insulin-sparing effects of some OADs, which allow a lower dose of insulin to be used, thereby reducing the potential for hypoglycaemia [2,6]. This evidence concerns the gene INS and Hypoglycemia.